CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...